Takeda has bought celiac disease therapy developer PvP Biologics, three years after acquiring an option to buy it in return for $35m in financing.

Pharmaceutical firm Takeda acquired one of its portfolio companies, US-based celiac disease drug developer PvP Biologics, yesterday in a deal sized at up to $330m. PvP was founded in 2011 out of a project submitted for University of Washington’s Genetically Engineered Machine contest that involved it using software designed by UW professor of biochemistry David…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.